IMRIS to develop radiation treatment with Varian

IMRIS (TSX:IM) and Varian Medical Systems (NYSE:VAR) have agreed to co-develop a radiation therapy suite that couples IMRIS’ magnetic resonance imaging technology with Varian’s TrueBeam radiotherapy system for use in treating a variety of cancers. “We are seeking to augment physicians’ ability to target cancerous tissue very precisely, even in areas of the body that [...]

Canaccord downgrades MethylGene

The sudden departure of MethylGene (TSX:MYG) CEO Donald Corcoran prompted Canaccord Genuity to downgrade the stock to “hold” and place its target price “under review.” The stock finished at 16 cents Monday. Analyst Neil Maruoka writes that the departure highlights the uncertainty of the company’s lead products. “Although the development plan for lead cancer drug [...]

Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]

« Previous Page